Shares of Espey Mfg. & Electronics Corp. ESP have gained 15.9% since the company reported its earnings for the quarter ended ...

Revenue: US$784.8m (down 13% from 1Q 2024). Net loss: US$79.0m (loss widened by 4.6% from 1Q 2024). US$2.23 loss per share (further deteriorated from US$2.14 loss in 1Q 2024). Looking ahead ...

May 13 - Anthony Edwards poured 11 of his 30 points into a 17-0 third-quarter flurry as the Minnesota ... Edwards also buried a pair of 3-pointers and a short jumper among his 11 points, while ...

It posted a net loss per share of 14 cents, compared with a loss of $3.61 a share ... has fallen 51.2% over the past 12 months, and 27% this year to date. Over the first quarter, the company ...

Edwards was underwhelming in Games 1 and 2, but he erased any doubt in Saturday's Game 3. In a Timberwolves win ... over Anthony Edwards in the third quarter, but the Timberwolves star certainly ...

INDIANAPOLIS — Donovan Mitchell refused to let another fourth-quarter ... 3-0 hole and used everything in its arsenal to hold on Friday. NBA Defensive Player of the Year Evan Mobley and key backup ...

Palantir (PLTR) stock fell 12% Tuesday as investors scrutinized the company's valuation and declining sales in its international business, even as its first quarter revenue blew past Wall Street's ...

P3 Health Partners (PIII) reaffirms 2025 guidance with strategic gains in operational efficiency, contract renegotiations & clinical metrics improvement.

Q2 2025 Earnings Call Transcript May 9, 2025 Operator: Good day, everyone, and welcome to the i3 Verticals Second Quarter 2025 Earnings Conference Call. Today’s call is being recorded and a replay ...

Earlier Friday, Enbridge reported a first-quarter profit of $2.3 billion, up from $1.4 billion in the same quarter last year. That amounted to $1.04 per share for the quarter ended March 31 ...

Good day, and welcome to the Q2 2025 ESCO Technologies, Inc. Earnings Conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a ...

It was found that glepaglutide, a long-acting GLP-2 analogue, when given twice weekly as subcutaneous delivery via auto-injector in SBS patients met the primary endpoint in the EASE 1 phase 3 trial.